News

Pembrolizumab paired with immunostimulator is safe and tolerable

Publish date: June 15, 2016

 

AT THE 2016 ASCO ANNUAL MEETING

The study was sponsored by Pfizer and Merck. Dr. Tolcher has ties to several companies, including Pfizer and Merck. Dr. Spigel has ties to several companies, including Pfizer.

Pages

Recommended Reading

NCI: Use of dug wells in New England linked with risk of bladder cancer
MDedge Hematology and Oncology
Smoking gun: DNA methylation in prostate cancer
MDedge Hematology and Oncology
FDA approves lenvatinib for advanced renal cell carcinoma
MDedge Hematology and Oncology
FDA approves atezolizumab for advanced urothelial carcinoma
MDedge Hematology and Oncology
VIDEO: Immune checkpoint inhibitor is efficacious as first-line therapy for advanced bladder cancer
MDedge Hematology and Oncology
MyPathway: Targeted therapies show promise in nonindicated tumors
MDedge Hematology and Oncology
No OS benefit with tasquinimod in mCRPC
MDedge Hematology and Oncology
Atezolizumab has good showing as first-line therapy in urothelial cancer
MDedge Hematology and Oncology
Baseline PSA at midlife predicts lethal prostate cancer
MDedge Hematology and Oncology
Immune agonist, checkpoint inhibitor combo shows good tolerability
MDedge Hematology and Oncology